#ASC39
LightNews LightNews
newsen.bsky.social
Ascletis Submits FDA IND for ASC39 to Combat Obesity with Selective Amylin Agonist#USA#Hong_Kong#Ascletis#ASC39#Amylin
Ascletis Submits FDA IND for ASC39 to Combat Obesity with Selective Amylin Agonist
Ascletis Pharma has submitted an Investigational New Drug application for ASC39, a selective amylin receptor agonist, aiming to revolutionize obesity treatment.
third-news.com
October 26, 2026 at 8:04 AM
taiwannews-zh.taiwansky.social
歌禮宣佈口服小分子選擇性胰澱素受體激動劑ASC39治療肥胖症的新藥臨床試驗申請已遞交美國FDA
歌禮宣佈口服小分子選擇性胰澱素受體激動劑ASC39治療肥胖症的新藥臨床試驗申請已遞交美國FDA
www.taiwannews.com.tw
November 1, 2026 at 2:43 AM
epsteinweb.bsky.social
EFTA01096609.jpg
#epsteinweb #efta01096609
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA01095993 | EFTA01096609 Code '_Custom Logbook Position Dese iption Serial Number Part Number TAG I MOD HW I MM Ref Ops Number(s) I ASC39 (PTI)SINGLE DAU DISPATCH SW TSRHR TSNHR TSOHR TSNLD TSNLD TSRLD TSNMO TSOMO TSRMO @=Adlustments (Used Hrs, Cye, Date) Comments Required Frequency Last CM Next Due Nadi) Avg Manhours Approx Price Manufacturer Date Type 5.6 Hrs 3 CI_ 21 Apt 1999 0.00 ASC39 AMI SINGLE DAU DISPATCH 5.6 Hrs 3 CA_ 21 Apt 1999 0.00 ASC40 HYDRAULIC SYSTEM MOD 5.6 Hrs 3 CI_ 21 Apt 1999 0.00 ASC40 AMI HYDRAULIC SYSTEM MOD 5.6 its 3 CtL 21 Apt 1999 0.00 ASC40 AM2 HYDRAULIC SYSTEM MOD 5.6 Hrs 3 CI_ 21 Apt 1999 0.00 ASC4I BAG COMP DECOMP ANNUNCIA 5.6 Hrs 3 CI_ 21 Apt 1999 21.00 970420 ASC42 ENGINE OIL REPLENISHER 5.6 Hrs 3 CI_ 21 Apt 1999 30.00 Airframe ASC 25 970390 Part Warranty Labor Warranty Airframe 970391 Airframe 970400 Airframe 970401 Airframe 970402 Airframe 970410 Airframe OE-IIS GV 572 Current Status Page 617 of 718 23 Oct 2014 O2014 Gulfstream Aerospace Corporation. All Rights Reserved. A General Dynamics Company EFTA01096609
May 9, 2026 at 8:28 AM
epsteinweb.bsky.social
EFTA01095903.jpg
#epsteinweb #efta01095903
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA01095330 | EFTA01095903 Code 'rCustom Logbook Position 970390 Desc iption Serial Number Part Number TAG I MOD FiW 1 MM Ref Ops Number(s) I SW TSRHR TSNHR TSOHR TSNLD TSOLD TSRLD TSNMO TSOMO TSRMO @=Adlustments (Used Hrs, Cye, Date) Comments Required Frequency Last CM Next Due ('vadi) Part Warranty Labor Warranty Avg Manhours Approx Price Manufacturer Date Type ASC39 (PTI)SINGLE DAU DISPATCH 251.0 Hrs 114 CiL 24 Sep 1998 0.00 ASC39 AMI SINGLE DAU DISPATCH 251.0 Hrs 114 CiL 25 Sep 1998 0.00 ASC40 AMI HYDRAULIC SYSTEM MOD 251.0 Hrs 114 CiL 16 Sep 1998 0.00 ASC40 AM2 HYDRAULIC SYSTEM MOD 251.0 Hrs 114 CiL 16 Sep 1998 0.00 ASC41 BAG COMP DECOMP ANNUNCIA 251.0 Hrs 114 CiL 27 Sep 1998 21.00 970420 ASC42 ENGINE OIL REPLENISHER 316.0 Hrs 139 CiL 28 Feb 1999 30.00 Airframe ASC 25 970421 ASC42 AMI ENG OIL REPLENISHER 316.0 Hrs 139 CiL 23 Feb 1999 0.00 Airframe 970391 Airframe 970401 Airframe 970402 Airframe 970410 Airframe Airframe N863MF GV 512 Current Status Page 574 of 663 16 May 2016 02016 Gulfstream Aerospace Corporation. All Rights Reserved. A General Dynamics Company EFTA01095903
May 9, 2026 at 7:55 AM
newsen.bsky.social
Ascletis Unveils Promising Obesity Treatment Advances at ADA 2026#USA#New_Orleans#Obesity_Treatment#ASC30#Ascletis_Pharma
Ascletis Unveils Promising Obesity Treatment Advances at ADA 2026
Ascletis Pharma showcased breakthrough obesity treatment data at the ADA 2026 Scientific Sessions, highlighting oral agents ASC30, ASC37, and ASC39.
third-news.com
June 8, 2026 at 12:20 AM
newsen.bsky.social
Ascletis Unveils Groundbreaking Fixed-Dose Combination Therapy for Obesity Management#USA#Hong_Kong#ASC30#Ascletis_Pharma#ASC39
Ascletis Unveils Groundbreaking Fixed-Dose Combination Therapy for Obesity Management
Ascletis Pharma announces a new fixed-dose combination of ASC30 and ASC39 aimed at obesity treatment, highlighting promising pharmacokinetics and patient compliance.
third-news.com
April 7, 2026 at 11:14 AM
newsen.bsky.social
ASC39: A Promising Oral Small Molecule for Obesity Management in Clinical Trials#USA#Hong_Kong#Obesity_Treatment#Ascletis_Pharma#ASC39
ASC39: A Promising Oral Small Molecule for Obesity Management in Clinical Trials
Ascletis Pharma's ASC39 shows remarkable efficacy and selectivity in obesity treatment. The drug is poised for FDA review and clinical trials.
third-news.com
March 17, 2026 at 10:13 AM
l2plabs.bsky.social
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans, Louisiana), highlighting its...
dlvr.it
June 8, 2026 at 12:12 AM
l2plabs.bsky.social
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
-Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study. The fixed dose combination had excellent oral bioavailability, drug exposure and a...
dlvr.it
April 7, 2026 at 11:03 AM
l2plabs.bsky.social
Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models
- In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide. EC50 for human amylin 1 receptor (hAMY1R) was 21.4 pM and 21.2 pM for ASC39...
dlvr.it
March 17, 2026 at 10:06 AM